ELDN ELEDON PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ELEDON PHARMACEUTICALS INC reported revenue of n/a, net income of −$31.6M and diluted EPS of −$0.27; for the fiscal year ended December 2025 revenue was n/a.
ELDN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$45.6M (margin n/a), EPS −$0.52
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income n/a, net income −$36.2M (margin n/a), EPS −$0.66
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$43.0M, net income −$117M (margin n/a), EPS −$4.73
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$88.4M, net income −$88.0M (margin n/a), EPS −$6.16
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$36.9M, net income −$34.5M (margin n/a), EPS −$2.33
ELDN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$31.6M, EPS −$0.27
- Quarter ended Mar 31, 2026: revenue n/a, net income −$39.0M, EPS −$0.33
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$10.4M, EPS −$0.10
- Quarter ended Sep 30, 2025: revenue n/a, net income −$17.5M, EPS −$0.21
- Quarter ended Jun 30, 2025: revenue n/a, net income −$11.2M, EPS −$0.13
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.50M, EPS −$0.08
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$44.6M, EPS $1.19
- Quarter ended Sep 30, 2024: revenue n/a, net income $77.0M, EPS −$0.28
- Quarter ended Jun 30, 2024: revenue n/a, net income −$44.9M, EPS −$0.92
- Quarter ended Mar 31, 2024: revenue n/a, net income −$23.6M, EPS −$0.65
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$30.1M, EPS −$0.91
- Quarter ended Sep 30, 2023: revenue n/a, net income −$9.91M, EPS −$0.33
- Quarter ended Jun 30, 2023: revenue n/a, net income −$65.8M, EPS −$2.74
- Quarter ended Mar 31, 2023: revenue n/a, net income −$10.8M, EPS −$0.75
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$58.4M, EPS −$4.09
- Quarter ended Sep 30, 2022: revenue n/a, net income −$10.5M, EPS −$0.73
- Quarter ended Jun 30, 2022: revenue n/a, net income −$9.25M, EPS −$0.65
- Quarter ended Mar 31, 2022: revenue n/a, net income −$9.86M, EPS −$0.69
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$8.81M, EPS −$0.60
- Quarter ended Sep 30, 2021: revenue n/a, net income −$9.82M, EPS −$0.66
ELDN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$62.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$47.3M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$39.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$28.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$28.9M, share buybacks n/a
ELDN balance sheet
- Jun 30, 2026: cash $6.80M, total assets $126M, total liabilities $54.1M, shareholders' equity $33.0M
- Mar 31, 2026: cash $6.15M, total assets $147M, total liabilities $46.2M, shareholders' equity $44.8M
- Dec 31, 2025: cash $22.8M, total assets $169M, total liabilities $32.2M, shareholders' equity $81.1M
- Sep 30, 2025: cash $3.67M, total assets $130M, total liabilities $38.8M, shareholders' equity $35.4M
- Jun 30, 2025: cash $5.74M, total assets $145M, total liabilities $38.9M, shareholders' equity $50.3M
- Mar 31, 2025: cash $8.50M, total assets $161M, total liabilities $46.7M, shareholders' equity $58.9M
- Dec 31, 2024: cash $20.5M, total assets $177M, total liabilities $59.3M, shareholders' equity $62.4M
- Sep 30, 2024: cash $6.75M, total assets $115M, total liabilities $38.5M, shareholders' equity $20.4M
Is ELDN profitable?
No. ELEDON PHARMACEUTICALS INC lost $98.6M over the last four quarters.
What is ELDN's EPS?
Diluted earnings per share over the last four quarters were −$0.91; −$0.27 in the latest quarter.